Abstract

Introduction: Drug combination is widely used to treat chronic inflammatory diseases. A similar strategy might be worth of interest to design plant-derived natural products to treat inflammatory conditions. Curcumin is a natural phenolic compound which shares anti-inflammatory activity with both flavocoxid, a flavonoid mixture of baicalin and catechin, and β-caryophyllene, a bicyclic sesquiterpene. The aim of this study was to investigate the synergy potential of curcumin with both flavocoxid and β-caryophyllene in human articular chondrocytes triggered with lipopolysaccharide (LPS), in an experimental in vitro model of osteoarthritis.Materials and Methods: Human articular chondrocytes were stimulated with LPS alone or in combination with different treatments. Total RNA was extracted 4 h after treatment to study interleukin 1β (IL-1β), NF-κB, and STAT3 mRNA expression. A drug combination study was designed choosing 5 doses to demonstrate a synergistic effect of compounds, according to Chou and Talalay method. A median-effect equation was applied and finally, the combination index (CI) was used to clarify the nature of the compounds interaction (synergistic versus additive versus antagonistic inhibitory effects); CI < 1, CI = 1, and CI > 1 indicated synergistic, additive, and antagonistic effects, respectively.Results: LPS prompted IL-1β expression. Curcumin, flavocoxid and β-caryophyllene suppressed IL-1β expression with different IC50. A synergistic action for the reduction of the inflammatory phenotype in human chondrocytes was observed for the combination curcumin-flavocoxid with a percentage from 10% to 90%, and for the combination curcumin-β-caryophyllene from 50% to 90%. IC50 doses of either flavocoxid, β-caryophyllene and curcumin alone or in combination were safe and did not affect cell vitality. Moreover, the same IC50 doses reduced the transcription factors NF-κB and STAT3 mRNA expression and interestingly the effects of the combinations were greater than the natural products alone, thus suggesting that the site where the synergy takes place could be at the signal transduction level.Discussion: The results suggest that curcumin synergizes with either flavocoxid or β-caryophyllene, exerting an anti-inflammatory activity and thus strongly suggesting the potential of a dual combination of these compounds for the management of osteoarthritis and unmasking a new feature of these natural products.

Highlights

  • Drug combination is widely used to treat chronic inflammatory diseases

  • Meta-analyses of eight randomized clinical trials enrolling more than 800 patients suffering from OA clearly pointed out and confirmed the significant efficacy of curcumin in the management of the inflammatory disease (Daily et al, 2016; Onakpoya et al, 2017)

  • This has been recently confirmed by a randomized doubleblind placebo controlled trial that exploited the safety and the efficacy of curcumin in combination with the anti-inflammatory phytochemical boswellic acid in patients suffering from OA (Haroyan et al, 2018)

Read more

Summary

Introduction

Drug combination is widely used to treat chronic inflammatory diseases. A similar strategy might be worth of interest to design plant-derived natural products to treat inflammatory conditions. The use of natural medicine has grown and a huge amount of people around the globe seeks remedy for their health problem in phytotherapy (Thomford et al, 2018a). This scenario has prompted the interest of the pharmaceutical industry in the research and development of new medicines to treat chronic diseases. Curcumin is a naturally occurring phenolic compound extracted as a yellow pigment from spice turmeric (Curcuma longa L.) It inhibits the inflammatory response by suppressing NF-κB signaling in rat chondrocytes and modulates collagen deposition, matrix metalloproteinase-13, and cell proliferation throughout the reduction of interleukin-1β (IL-1β) (Wang et al, 2017). The systemic therapeutic potential of curcumin has been demonstrated in OA using an OA rat model (Ratanavaraporn et al, 2017), while the clinical efficacy of this compound has been confirmed in patients suffering from the inflammatory pathology (Liu et al, 2018)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call